{"organizations": [], "uuid": "c88e72b05965395e41065f130642b1d77567530a", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/8", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/04/24/pr-newswire-sangamo-therapeutics-announces-proposed-public-offering-of-common-stock.html", "country": "US", "domain_rank": 767, "title": "Sangamo Therapeutics Announces Proposed Public Offering of Common Stock", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-25T00:02:00.000+03:00", "replies_count": 0, "uuid": "c88e72b05965395e41065f130642b1d77567530a"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/04/24/pr-newswire-sangamo-therapeutics-announces-proposed-public-offering-of-common-stock.html", "ord_in_thread": 0, "title": "Sangamo Therapeutics Announces Proposed Public Offering of Common Stock", "locations": [], "entities": {"persons": [], "locations": [{"name": "richmond", "sentiment": "none"}, {"name": "calif.", "sentiment": "none"}], "organizations": [{"name": "sangamo therapeutics", "sentiment": "negative"}, {"name": "sangamo therapeutics, inc.", "sentiment": "neutral"}, {"name": "sangamo", "sentiment": "none"}, {"name": "bofa merrill lynch", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "RICHMOND, Calif., April 24, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) today announced that it has commenced an underwritten public offering of $200.0 million of shares of its common stock. All of the shares are being offered by Sangamo. In addition, Sangamo expects to grant the underwriters of the offering a 30-day option to purchase up to an additional $30.0 million of shares of its common stock solely to cover overallotments at the public offering price, less the underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering will be completed, or as to the actual size or terms of the offering.\nSangamo anticipates using the net proceeds from the offering to support its own and its partnered gene therapy, genome editing, cell therapy and gene regulation product candidates and research programs, its manufacturing facilities and other business development activities, as well as for general corporate purposes, including working capital.\nBofA Merrill Lynch, J.P. Morgan Securities LLC and Cowen and Company, LLC are acting as joint book-running managers for the offering.\nA registration statement relating to the shares was previously filed with and became effective by rule of the Commission. The offering is being made solely by means of a prospectus. A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the Commission and will be available on the Commission's website located at http://www.sec.gov . A copy of the preliminary prospectus supplement and accompanying prospectus relating to the offering, when available, may be obtained from: BofA Merrill Lynch, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, Attention: Prospectus Department, or by email at dg.prospectus_requests@baml.com ; or from J.P. Morgan Securities LLC c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (866) 803-9204; or from Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (631) 274-2806.\nThis press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.\nAbout Sangamo Therapeutics\nSangamo Therapeutics, Inc. is focused on translating ground-breaking science into genomic therapies that transform patients' lives using the Company's industry leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy.\nForward Looking Statements\nThis press release contains regarding Sangamo's current expectations. These include, without limitation, references to Sangamo's expectations regarding the completion, timing and size of the public offering, its expectations with respect to granting the underwriters a 30-day option to purchase additional shares and its anticipated use of net proceeds from the offering. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, related to completion of the public offering on the anticipated terms or at all, market conditions and the satisfaction of customary closing conditions related to the public offering. These and other are described more fully in the section captioned \"Risk Factors\" in the preliminary prospectus supplement related to the public offering to be filed with the Commission as well as Sangamo's Current Report on Form 8-K filed with the Commission on April 17, 2018 and other filings. Forward-looking statements contained in this announcement are made as of this date, and Sangamo undertakes no duty to update such information except as required under applicable law.\nView original content with multimedia: http://www.prnewswire.com/news-releases/sangamo-therapeutics-announces-proposed-public-offering-of-common-stock-300635752.html\nSOURCE Sangamo Therapeutics, Inc.", "external_links": ["http://www.sec.gov/", "http://www.prnewswire.com/news-releases/sangamo-therapeutics-announces-proposed-public-offering-of-common-stock-300635752.html"], "published": "2018-04-25T00:02:00.000+03:00", "crawled": "2018-04-25T00:28:05.034+03:00", "highlightTitle": ""}